SCHEMBL5568255

SCHEMBL5568255

COc1cc2ncnc(-c3cccc(N)c3)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.64
KDR P35968 5/20 0.61
RET P07949 4/20 0.61
EGFR P00533 8/20 0.52
ATM Q13315 2/20 0.49
ENPP1 P22413 1/20 0.48
SRC P12931 3/20 0.48
LCK P06239 1/20 0.48
EPHB2 P29323 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ABL1 P00519 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
FBP1 P09467 2/20 0.47
CYP2D6 P10635 2/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 2/20 0.47
MAPK14 Q16539 2/20 0.47
MKNK1 Q9BUB5 2/20 0.47
FGFR1 P11362 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28098004 0.91 KIT (0.58) KITKDRRETEGFRATM
SCHEMBL6181412 0.84 EGFR (0.63) KITKDRRETEGFRATM
SCHEMBL5569432 0.84 KIT (0.69) KITKDRRETEGFRENPP1
SCHEMBL4782102 0.84 WHR1 (0.61) KITKDRRETEGFRATM
SCHEMBL2126095 0.83 EGFR (0.61) KITKDREGFRSRCLCK
SCHEMBL2125179 0.83 EGFR (0.61) KITKDRRETEGFRSRC
SCHEMBL5568252 0.81 PIK3CD (0.56) KITKDREGFRENPP1MAPK14
SCHEMBL27734225 0.80 RET (0.44) KITKDRRETEGFRABL1
SCHEMBL15516134 0.78 KIT (1.00) KITKDRRETEGFRENPP1
SCHEMBL295421 0.78 WHR1 (0.52) KDRRETEGFRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106083740-A A kind of 4 anilinoquinazoline derivatives containing 1,2,3 triazoles and preparation method 江苏开放大学 2016-11-09 CN claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT KIT 3692/4885KDR 2712/4885RET 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.